All In Biotech

Drug Trial Radar · NCT07098663

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Study to Assess Food Effect, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of MKP10241 in Healthy and Obese Adult Participants, With and Without Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Aug 12, 2025

Primary completion

Jan 19, 2026

Study completion Apr 17, 2026

Sponsor

Lead sponsor
Mankind Pharma LimitedIndustry
Sponsor type
Industry
Collaborators
Emerald Clinical Inc.
First posted
Aug 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts. The main parameters it aims to answers are : 1. Does food effects the pharmacokinetic parameters following a single dose of MKP10241 in healthy participants? 2. Will multiple ascending doses of MKP10241 in obese participants with or without T2DM characterize changes in the plasma pharmacokinetic profile and pharmacodynamic effects? 3. What treatment emergent adverse events or discontinuation is experienced following single and multiple ascending doses of MKP10241 in healthy and obese participants with or without T2DM? This study will be compared against a placebo which is matched in appearance to MKP10241 at dosage strengths. Participants will: 1. Part 1: Take MKP10241 400 mg or Placebo on Day 1 and Day 8. Part 2: Take MKP10241 200 mg, 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 Part 3: Take MKP10241 300 mg and 400 mg or Placebo daily from Day 1 to Day 28 2. Visit the clinical research unit for dose administration, admission or follow up. 3. Will be monitored by the Safety Monitoring Committee.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Food Effect
  • Safety and Tolerability
  • Obesity

Interventions

  • MKP10241Drug

    Oral liquid suspension of unit dose strength 6.6 mg/mL

  • PlaceboDrug

    Oral liquid suspension matched in appearance to MKP10241 at dosage strengths

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Food effect of single dose of MKP10241 on Maximum concentration of drug (Cmax)Time frame: 18 days
  2. Part 1 - Food effect of single dose of MKP10241 on Apparent total clearance of drug (CL/F)Time frame: 18 days
  3. Part 1 - Food effect of single dose of MKP10241 on Time to maximum concentration (Tmax)Time frame: 18 days
  4. Part 1 - Food effect of single dose of MKP10241 on elimination half life (t1/2 )Time frame: 18 days
  5. Part 1 - Food effect of single dose of MKP10241 on lag time (Tlag)Time frame: 18 days
  6. Part 1 - Food effect of single dose of MKP10241 on Apparent Volume of distribution of drug (V/F)Time frame: 18 days
  7. Part 1 - Food effect of single dose of MKP10241 on Area under the curve from time 0 to 24hrs - AUC (0-24h)Time frame: 18 days
  8. Part 1 - Food effect of single dose of MKP10241 on AUC(0-last)Time frame: 18 days
  9. Part 1 - Food effect of single dose of MKP10241 on AUC(0-inf)Time frame: 18 days
  10. Part 2 - To evaluate the incidence of treatment emergent adverse events and participant tolerance of MKP10241 following multiple doses in obese participantsTime frame: 35 days
  11. Part 3 - To evaluate the incidence of treatment emergent adverse events and participant tolerance of MKP10241 following multiple doses in obese participants with T2DM.Time frame: 35 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Bayswater, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.